Everyone's talking about Eli Lilly and Novo Nordisk. Both have tripled. The GLP-1 thesis is priced in.
But here's what most investors miss: the second-order effects are just getting started.
When 40% of Americans are obese and a new drug class can help them lose 15-25% of body weight, EVERY industry gets disrupted. Not just pharma.
This is where the asymmetric opportunities live.
The Second-Order Winners
Hims & Hers (HIMS) — The Access Play
The thesis: Telehealth platform now offering compounded GLP-1s at a fraction of brand-name cost. 70%+ revenue growth.
Why it works:
- Brand-name GLP-1s cost ~$1,000/month
- Compounded versions through HIMS are cheaper
- Telehealth moat for weight loss prescriptions
- Young, tech-savvy customer base expanding
The risk: FDA crackdown on compounding (Q1-Q2 2025). This is binary.
Verdict: Highest-conviction second-order winner IF regulatory risk resolves favorably. Size for the binary outcome.
InMode (INMD) — The Body Contouring Play
The thesis: GLP-1 patients lose weight fast. They're left with loose skin, "Ozempic face," and need for body contouring.
InMode makes minimally invasive body sculpting devices.
Why it works:
- Trading at 8x P/E (value territory)
- Direct beneficiary of post-weight-loss aesthetics
- Already profitable
- Medical aesthetics = cash-pay, high margin
The risk: Israeli company (geopolitical), consumer discretionary exposure.
Verdict: Value play with clear GLP-1 tailwind.
BellRing Brands (BRBR) — The Protein Play
The thesis: GLP-1 patients need protein to preserve muscle mass during weight loss. Doctors recommend high protein intake.
BellRing owns Premier Protein — the #1 protein shake brand.
Why it works:
- Medical necessity, not lifestyle choice
- Direct nutritional companion to GLP-1 therapy
- Already seeing elevated demand
Verdict: Solid, lower-risk second-order play.
The Second-Order Losers
ResMed (RMD) — The Sleep Apnea Victim
This is the clearest loser in the GLP-1 universe.
The data: SURMOUNT-OSA trial showed 63% reduction in sleep apnea severity with GLP-1 treatment.
Obesity is the #1 cause of sleep apnea. ResMed makes CPAP machines. Do the math.
The damage:
- ~13% of revenue directly at risk
- Stock already down significantly
- Long-term secular decline
Bull case for RMD: International growth, not all sleep apnea is obesity-related, GLP-1 adoption slower than feared.
Verdict: Best short candidate. Clear causal link, quantifiable revenue impact.
Hershey (HSY) — The Craving Casualty
The thesis: GLP-1 drugs don't just cause weight loss — they eliminate cravings and "food noise."
Patients report:
- Reduced desire for sweets
- Less compulsive snacking
- Changed relationship with food
Hershey = pure play on impulse snacking.
The damage:
- Already down ~30% from highs
- Cocoa inflation compounding problems
- Craving reduction is existential long-term
Verdict: Already down a lot, but secular headwind is real.
DaVita (DVA) — The Dialysis Decline
The thesis: Obesity → diabetes → kidney failure → dialysis.
If obesity falls, eventually dialysis demand falls.
The nuance: Very long duration (10-20 years). Current patients won't be cured. Affects new patient growth, not existing base.
Verdict: Real but long-dated. Not a near-term trade.
Trade Setups: Long/Short Pairs
Pair 1: Long HIMS / Short RMD
Thesis: GLP-1 access enabler vs. GLP-1 victim
Risk: HIMS regulatory; RMD international growth
Pair 2: Long INMD / Short HSY
Thesis: Body contouring winner vs. craving victim
Risk: INMD geopolitical; HSY already down a lot
Pair 3: Long BRBR / Short HSY
Thesis: Protein (necessity) vs. candy (craving reduction)
Risk: Both consumer discretionary exposure
Summary Table
| Ticker | Direction | Conviction | Thesis |
|---|---|---|---|
| HIMS | Long | High | GLP-1 access/compounding |
| INMD | Long | High | Body contouring demand |
| BRBR | Long | Medium | Protein for muscle preservation |
| RMD | Short | Highest | Sleep apnea decline |
| HSY | Short | High | Craving destruction |
| DVA | Short | Medium | Dialysis decline (long-dated) |
Smart Money Tracking
Who's buying the winners? Who's selling the losers?
Congressional healthcare trades. Institutional positioning in RMD and HSY. Insider activity at threatened companies.
We track 14 data sources and alert when smart money aligns with the GLP-1 thesis.
Track Healthcare Signals → AlphaSignal
Bottom Line
- LLY/NVO are priced in — look for second-order effects
- HIMS is the highest-beta winner (with regulatory risk)
- INMD is the value play (8x P/E, direct beneficiary)
- RMD is the clearest short (63% sleep apnea reduction)
- Pair trades reduce directional risk
The GLP-1 revolution extends far beyond pharma. Trade the ripple effects.